MedTrace Logo

Safety and Efficacy of the Coronavirus Disease 2019 Vaccine in Hemodialysis Patients

NCT04944433 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 950

Last updated 2022-08-05

No results posted yet for this study

Summary

It is unknown whether Coronavirus disease 2019 vaccines confer the same high level of protection in patients with kidney disease as reported for participants in recent trials, who were generally healthy. Objectives: To evaluate the safety and efficacy of Coronavirus disease 2019 vaccines in hemodialysis patients.

Conditions

  • Coronavirus Disease 2019 Vaccines
  • Renal Dialysis

Sponsors & Collaborators

  • Ministerio de Salud de Ciudad Autónoma de Buenos Aires

    collaborator OTHER_GOV

  • University of Buenos Aires

    collaborator OTHER

  • Hospital Italiano de Buenos Aires

    lead OTHER

Principal Investigators

  • Guillermo IP Rosa Diez, MD · Hospital Italiano de Buenos Aires

  • Jorge SI Geffner · University of Buenos Aires

  • Fernando SI Lombi · Sociedad Argentina de Nefrología

  • Marina SI Papaginovic · Sociedad Argentina de Nefrología

  • Ricardo SI Heguilen · Sociedad Argentina de Nefrología

  • Luciana Fernandez SI Paganti · Sociedad Argentina de Nefrología

  • Soledad SI Crucelegui · Hospital Italiano de Buenos Aires

  • Vanina SI Pagotto · Hospital Italiano de Buenos Aires

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-09
Primary Completion
2022-08-04
Completion
2022-08-04

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04944433 on ClinicalTrials.gov